$2.67
8.54% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US9840152063
Symbol
XBIO
Sector
Industry

Xenetic Biosciences, Inc. Stock price

$2.67
-1.39 34.24% 1M
-1.91 41.64% 6M
-1.32 33.08% YTD
-1.72 39.18% 1Y
-8.23 75.50% 3Y
-4.45 62.50% 5Y
-789.33 99.66% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.21 8.54%
ISIN
US9840152063
Symbol
XBIO
Sector
Industry

Key metrics

Market capitalization $3.79m
Enterprise Value $-2.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.84
EV/Sales (TTM) EV/Sales -0.95
P/S ratio (TTM) P/S ratio 1.52
P/B ratio (TTM) P/B ratio 0.63
Revenue growth (TTM) Revenue growth -1.56%
Revenue (TTM) Revenue $2.50m
EBIT (operating result TTM) EBIT $-3.50m
Free Cash Flow (TTM) Free Cash Flow $-2.82m
Cash position $6.17m
EPS (TTM) EPS $-2.57
P/S forward 1.35
EV/Sales forward negative
Short interest 0.31%
Show more

Is Xenetic Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Xenetic Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Xenetic Biosciences, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Xenetic Biosciences, Inc.:

Hold
100%

Financial data from Xenetic Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.50 2.50
2% 2%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.42 3.42
4% 4%
137%
- Research and Development Expense 2.58 2.58
26% 26%
103%
-3.50 -3.50
23% 23%
-140%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.50 -3.50
22% 22%
-140%
Net Profit -3.96 -3.96
4% 4%
-158%

In millions USD.

Don't miss a Thing! We will send you all news about Xenetic Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenetic Biosciences, Inc. Stock News

Neutral
Accesswire
7 days ago
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its...
Neutral
Accesswire
14 days ago
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma FRAMINGHAM, MA / ACCESS Newswire / March 1...
Neutral
Accesswire
20 days ago
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025...
More Xenetic Biosciences, Inc. News

Company Profile

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Head office United States
CEO James Parslow
Employees 2
Founded 2011
Website www.xeneticbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today